Alzheimer's Disease and the Amyloid β Protein

Alzheimer’s disease (AD) is characterized by the deposition of amyloid in the extracellular compartment of the brain in the form of congophilic amyloid angiopathy (CAA) and amyloid plaques (APs). Intracellular neurofibrillary tangles (NFTs) (Terry, 1963) formed from the abnormally phosphorylated cytoskeletal protein tau are also seen (Lee et al., 1991). The identification of the amyloid b protein (Ab) in CAA and APs (Glenner and Wong, 1984; Masters et al., 1985) led to the cloning of the amyloid protein precursor (APP) (Kang et al., 1987). The discovery of familial AD (FAD) mutations in the APP gene (Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell et al., 1991; Naruse et al., 1991; Tanzi and Hyman, 1991) has supported the view that a defect in APP metabolism or function is directly involved in AD pathogenesis. The demonstration that mutations in the tau gene can lead to non-Alzheimer dementias with neurofibrillary pathology, lacking Ab plaques (reviewed by Spillantini and Goedert, 1998), has reinforced the view that the NFTs are a secondary phenomenon in the pathogenesis of AD. It has long been argued that the deposition of amyloid is an early step in AD pathogenesis (Masters et al., 1985; Hardy and Higgins, 1992; Masters and Beyreuther, 1993). The term amyloid refers to insoluble proteinaceous deposits that are congophilic and exhibit red– green birefringence in the presence of plane polarized light (Kisilevsky, 1994). Implicit in much of the research on the role of APP and Ab has been the assumption that deposits of amyloid are toxic to the brain (Jarrett and Lansbury, 1993) and that these deposits are the underlying cause of AD. The observation that Ab peptides when “aged” (incubated to form amyloid fibrils) become toxic to neurons in culture (Yankner et al., 1989; Frautschy et al., 1991; Kowall et al., 1991; Pike et al., 1991; Howlett et al., 1995) has further supported this view. The amyloid cascade hypothesis of AD, as formalized by Hardy and Higgins (1992), states that Ab “precipitates to form amyloid and, in turn, causes neurofibrillary tangles and cell death.” However, this hypothesis has been challenged (see, e.g., Davis and Chisholm, 1997; Hardy, 1997b). It has been argued that the deposition of amyloid does not correlate with dementia (Terry et al., 1991; Arriagada et al., 1992; Roses, 1994; Samuel et al., 1994; Braak and Braak, 1996), although the failure to observe a correlation may be related to the method by which AP load is measured (Cummings and Cotman, 1995). Whether amyloid deposits have a pathogenic role remains a controversial issue.

[1]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.

[2]  S. Tsuji,et al.  Mis-sense mutation Val→Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease , 1991, The Lancet.

[3]  A. Paetau,et al.  A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1 , 1998, Nature Medicine.

[4]  B. Hyman,et al.  APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.

[5]  N Butters,et al.  Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. , 1994, Archives of neurology.

[6]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D. Selkoe,et al.  Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.

[9]  B. Hyman,et al.  Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.

[10]  A. Alzheimer Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[11]  M. Won,et al.  Behavioral and Neuropathologic Changes Induced by Central Injection of Carboxyl‐Terminal Fragment of β‐Amyloid Precursor Protein in Mice , 1998, Journal of neurochemistry.

[12]  S. Younkin,et al.  Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. , 1992, Science.

[13]  Davis Jn nd,et al.  The 'amyloid cascade hypothesis' of AD: decoy or real McCoy? , 1997 .

[14]  J. Hardy,et al.  A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). , 1997, Human molecular genetics.

[15]  B. Winblad,et al.  The significance of the Swedish APP670/671 mutation for the development of Alzheimer's disease amyloidosis , 1994, Neurochemistry International.

[16]  M. Mattson,et al.  beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[17]  G. Cole,et al.  Effects of injected Alzheimer beta-amyloid cores in rat brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Getz,et al.  Isoform-specific binding of apolipoprotein E to beta-amyloid. , 1994, The Journal of biological chemistry.

[19]  K. Kawasaki,et al.  Amyloid β Protein Potentiates Ca2+ Influx Through L‐Type Voltage‐Sensitive Ca2+ Channels: A Possible Involvement of Free Radicals , 1997, Journal of neurochemistry.

[20]  J. Trojanowski,et al.  A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. , 1991, Science.

[21]  D. Selkoe,et al.  Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. , 1998, Biochemistry.

[22]  G. Landreth,et al.  Identification of Microglial Signal Transduction Pathways Mediating a Neurotoxic Response to Amyloidogenic Fragments of β-Amyloid and Prion Proteins , 1999, The Journal of Neuroscience.

[23]  H. Braak,et al.  Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis , 1996, Acta Neuropathologica.

[24]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[25]  K Namekata,et al.  Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. , 1998, The American journal of pathology.

[26]  P. Greengard,et al.  Alzheimer Amyloid-β Peptide Forms Denaturant-Resistant Complex with Type ε3 but Not Type ε4 Isoform of Native Apolipoprotein E , 1996, Molecular medicine.

[27]  Y. Sakaki,et al.  Genomic organization of the human-amyloid beta-protein precursor gene. , 1990, Gene.

[28]  B. Ghetti,et al.  A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. , 1991, Science.

[29]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[30]  M. Smith,et al.  Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. , 1998, The American journal of pathology.

[31]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[32]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[33]  D. Selkoe,et al.  Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. , 1992, Science.

[34]  J. Hardy,et al.  Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene , 1991, Nature.

[35]  R. Davidson,et al.  Amyloid beta-peptide (AβP) potentiates a nimodipine-sensitive L-type barium conductance in N1E-115 neuroblastoma cells , 1994, Brain Research.

[36]  D. Mann,et al.  Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome , 1996, Nature Medicine.

[37]  K. Hsiao Transgenic mice expressing Alzheimer amyloid precursor proteins , 1998, Experimental Gerontology.

[38]  M. Goedert,et al.  Tau protein pathology in neurodegenerative diseases , 1998, Trends in Neurosciences.

[39]  L. Villa-komaroff,et al.  Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. , 1989, Science.

[40]  C. Behl,et al.  Hydrogen peroxide mediates amyloid β protein toxicity , 1994, Cell.

[41]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[43]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[44]  J. Ulrich,et al.  Alzheimer's Disease: A Description of the Structural Lesions , 1991, Brain pathology.

[45]  T. Oltersdorf,et al.  Cleavage of amyloid beta peptide during constitutive processing of its precursor. , 1990, Science.

[46]  R. Martins,et al.  Characterization of the Binding of Amyloid‐β Peptide to Cell Culture‐Derived Native Apolipoprotein E2, E3, and E4 Isoforms and to Isoforms from Human Plasma , 1997, Journal of neurochemistry.

[47]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[48]  Hugo Vanderstichele,et al.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.

[49]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[50]  M. Mattson,et al.  A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Selkoe,et al.  Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.

[52]  D. Selkoe,et al.  Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. , 1994, The Journal of biological chemistry.

[53]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[54]  A. Roses Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: (β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of Disease , 1994, Journal of neuropathology and experimental neurology.

[55]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[56]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[57]  M. Mattson,et al.  Cytochalasins Protect Hippocampal Neurons Against Amyloid β‐Peptide Toxicity: Evidence that Actin Depolymerization Suppresses Ca2+ Influx , 1995, Journal of neurochemistry.

[58]  J. Hardy,et al.  Increased Aβ42(43) from cell lines expressing presenilin 1 mutations , 1998, Annals of neurology.

[59]  Brian J Cummings,et al.  Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity , 1995, The Lancet.

[60]  A. Patel,et al.  Presenilins and early-onset familial Alzheimer's disease. , 1997, Neuroreport.

[61]  M. Emmerling,et al.  Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[62]  R. Terry THE FINE STRUCTURE OF NEUROFIBRILLARY TANGLES IN ALZHEIMER'S DISEASE , 1963, Journal of neuropathology and experimental neurology.

[63]  B. Hyman,et al.  Alzheimer's mutation , 1991, Nature.

[64]  M. Mattson,et al.  Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[65]  G. Forloni,et al.  Oxidative stress after acute and chronic application of β-amyloid fragment 25–35 in cortical cultures , 1996, Neuroscience Letters.

[66]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[67]  C. Masters,et al.  Strategic Thoughts on the Alzheimer’s Disease Amyloid Protein Precursor: The Way Forward , 1994 .

[68]  M. Mattson,et al.  Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF , 1993, Brain Research.

[69]  M. Mattson,et al.  β-Amyloid Peptide Free Radical Fragments Initiate Synaptosomal Lipoperoxidation in a Sequence-Specific Fashion: Implications to Alzheimer′s Disease , 1994 .

[70]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[71]  H. Brewer,et al.  Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments , 1994, Nature.

[72]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.

[73]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[74]  S. Younkin,et al.  Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. , 1993, Science.

[75]  P. Lansbury,et al.  A detergent-insoluble membrance compartment contains Aβ in vivo , 1998, Nature Medicine.

[76]  Carl W. Cotman,et al.  In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.

[77]  Mark P. Mattson,et al.  β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease , 1993, Trends in Neurosciences.

[78]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[79]  M. Beal,et al.  An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[80]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[81]  M. Ball,et al.  Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.

[82]  Xi Chen,et al.  An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease , 1997, Nature.

[83]  R. Wetzel,et al.  Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[84]  L. Mucke,et al.  Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[85]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[86]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[87]  M. Tabaton,et al.  Amyloid‐β Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress , 1998, Journal of neurochemistry.

[88]  D. Small,et al.  Role of Proteoglycans in Neural Development, Regeneration, and the Aging Brain , 1996, Journal of neurochemistry.

[89]  R. Doms,et al.  Detection of a Novel Intraneuronal Pool of Insoluble Amyloid β Protein that Accumulates with Time in Culture , 1998, The Journal of cell biology.